StockNews.AI
HRTX
StockNews.AI
3 hrs

Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

1. Heron Therapeutics appointed Thomas Cusack to its Board of Directors. 2. Cusack has over 20 years in investment management and corporate finance. 3. His role follows a cooperation agreement with Rubric Capital Management. 4. The appointment aims to enhance corporate governance and performance. 5. Heron focuses on therapeutic innovations for acute care and oncology.

5m saved
Insight
Article

FAQ

Why Bullish?

The appointment of an experienced director, Cusack, suggests potential for improved governance and performance. Historical precedent shows strategic board appointments can positively influence stock prices, as seen with other biotech firms enhancing oversight.

How important is it?

The addition of Cusack may lead to strategic changes beneficial for HRTX's growth. His experience could translate to effective governance, enhancing investor trust and potentially the stock price.

Why Long Term?

Board changes typically influence corporate direction over time, affecting long-term stock performance, similar to past biotech developments that reinforced investor confidence.

Related Companies

RUBRSBRA
October 29, 2025 17:58 ET  | Source: Heron Therapeutics, Inc. CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025. Mr. Cusack was appointed as a director of Heron as of October 27, 2025.  Mr. Cusack has more than 20 years of experience in investment management and corporate finance.  Most recently, from 2011 to 2025, he served as a Managing Director of Starboard Value LP, a New York-based investment fund with approximately $9 billion in assets under management known for its active approach to investing in public companies.  In this capacity, Mr. Cusack played a central role in evaluating investment opportunities, developing new operating strategies, and working closely with boards and management teams to improve performance and corporate governance.  Prior to his tenure at Starboard Value, from 2006 to 2011, he was an investment banker at Barclays Capital and Lehman Brothers focusing on Mergers & Acquisitions within the Technology, Media, & Telecom sectors.  Mr. Cusack holds a B.S. in Finance & Accounting from the Leonard N. Stern School of Business at New York University.   “We are pleased to welcome Tom to Heron’s Board of Directors,” said Craig Collard, Chief Executive Officer of Heron. “Tom will undoubtedly bring a wealth of perspective to benefit our efforts to build momentum at Heron.” About Heron Therapeutics, Inc. Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit www.herontx.com. Forward-looking Statements This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law. Investor Relations and Media Contact: Ira DuarteExecutive Vice President, Chief Financial OfficerHeron Therapeutics, Inc.iduarte@herontx.com858-251-4400

Related News